-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eli Lilly recently announced that the US government has agreed to purchase at least 100,000 doses of 700 mg of Bamlanivimab (LY-CoV555) and 1,400 mg of etesevimab (LY-CoV016) together.
Bamlanivimab and etesevimab have recently obtained emergency use authorization together to treat mild to moderate COVID-19 hospitalized patients.
COVID-19 In addition, the National Institutes of Health (NIH) recently updated its COVID-19 treatment guidelines, recommending the use of bamlanivimab in combination with etesevimab to treat patients with mild to moderate COVID-19 who are at high risk of clinical progression.
The US government stated that it will provide neutralizing antibodies to patients for free, although medical institutions may charge fees for the management of the product .
diagnosis
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here